BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50:74-87. [PMID: 29167021 DOI: 10.1016/j.pathol.2017.09.006] [Cited by in Crossref: 162] [Cited by in F6Publishing: 171] [Article Influence: 32.4] [Reference Citation Analysis]
Number Citing Articles
1 Garg R, Sambamoorthi U, Tan X, Basu SK, Haggerty T, Kelly KM. Impact of Diffuse Large B-Cell Lymphoma on Mammography and Bone Density Testing in Women. J Prim Prev 2021;42:143-62. [PMID: 33710443 DOI: 10.1007/s10935-021-00621-8] [Reference Citation Analysis]
2 Cui Q, Vari F, Cristino AS, Salomon C, Rice GE, Sabdia MB, Guanzon D, Palma C, Mathew M, Talaulikar D, Jain S, Han E, Hertzberg MS, Gould C, Crooks P, Thillaiyampalam G, Keane C, Gandhi MK. Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphoma. Oncotarget 2018;9:34644-57. [PMID: 30410665 DOI: 10.18632/oncotarget.26141] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
3 Bauer M, Jasinski-Bergner S, Mandelboim O, Wickenhauser C, Seliger B. Epstein-Barr Virus-Associated Malignancies and Immune Escape: The Role of the Tumor Microenvironment and Tumor Cell Evasion Strategies. Cancers (Basel) 2021;13:5189. [PMID: 34680337 DOI: 10.3390/cancers13205189] [Reference Citation Analysis]
4 Yu B, Wang B, Wu Z, Wu C, Ling J, Gao X, Zeng H. LncRNA SNHG8 Promotes Proliferation and Inhibits Apoptosis of Diffuse Large B-Cell Lymphoma via Sponging miR-335-5p. Front Oncol 2021;11:650287. [PMID: 33816305 DOI: 10.3389/fonc.2021.650287] [Reference Citation Analysis]
5 Liang Y, Zhang H, Wu Y, Li M. Incidence and survival trends in patients with primary tonsillar lymphoma: a large population-based study. Eur Arch Otorhinolaryngol. [DOI: 10.1007/s00405-022-07363-1] [Reference Citation Analysis]
6 Dong H, Wang Q, Zhang G, Li N, Yang M, An Y, Xie L, Li H, Zhang L, Zhu W, Zhao S, Zhang H, Guo X. OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma. Cancer Med 2020;9:1790-7. [PMID: 31918459 DOI: 10.1002/cam4.2829] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang Y, Zhao R, Jiao X, Wu L, Wei Y, Shi F, Zhong J, Xiong L. Small Extracellular Vesicles: Functions and Potential Clinical Applications as Cancer Biomarkers. Life (Basel) 2021;11:1044. [PMID: 34685415 DOI: 10.3390/life11101044] [Reference Citation Analysis]
8 Berendsen MR, Stevens WBC, van den Brand M, van Krieken JH, Scheijen B. Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance. Cancers (Basel) 2020;12:E3553. [PMID: 33260693 DOI: 10.3390/cancers12123553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Hu L, Wu F, Wang H, Zhu W, Wang J, Yu F, Zhai Z. Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient. Front Immunol 2021;12:665230. [PMID: 33953727 DOI: 10.3389/fimmu.2021.665230] [Reference Citation Analysis]
10 Song S, Li Y, Zhang K, Zhang X, Huang Y, Xu M, Li S, Guan X, Yang T, Liu Z, Jiang J, Luo Y, Lan Y. Cancer Stem Cells of Diffuse Large B Cell Lymphoma Are Not Enriched in the CD45+CD19- cells but in the ALDHhigh Cells. J Cancer. 2020;11:142-152. [PMID: 31892981 DOI: 10.7150/jca.35000] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Xu Y, Sun W, Li F. De Novo CD5+ Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances. Clinical Lymphoma Myeloma and Leukemia 2020;20:e782-90. [DOI: 10.1016/j.clml.2020.05.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Hunter E, Mccord R, Ramadass AS, Green J, Westra JW, Mundt K, Akoulitchev A. Comparative molecular cell-of-origin classification of diffuse large B-cell lymphoma based on liquid and tissue biopsies. transl med commun 2020;5. [DOI: 10.1186/s41231-020-00054-1] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Li X, Qi S, Jiao Y, Gao J, Du H. A case report of primary central nervous system lymphoma with intestinal obstruction as the initial symptom. Medicine (Baltimore) 2018;97:e0080. [PMID: 29517670 DOI: 10.1097/MD.0000000000010080] [Reference Citation Analysis]
14 Shawky SA, El-borai MH, Khaled HM, Guda I, Mohanad M, Abdellateif MS, Zekri AN, Bahanasy AA. The prognostic impact of hypermethylation for a panel of tumor suppressor genes and cell of origin subtype on diffuse large B-cell lymphoma. Mol Biol Rep 2019;46:4063-76. [DOI: 10.1007/s11033-019-04856-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
15 Wienerroither V, Sauerschnig M, Beham-Schmid C, Mathew E, El-Shabrawi A, Mischinger HJ, Kornprat P. Operative R0 resection of diffuse large B-cell lymphoma of the pelvis: a case report. J Med Case Rep 2018;12:293. [PMID: 30314526 DOI: 10.1186/s13256-018-1838-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Zhou M, Wang J, Li CP, Xu JY, Chen B. Autologous Cytokine-Induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission. Onco Targets Ther 2020;13:5879-85. [PMID: 32606798 DOI: 10.2147/OTT.S254291] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Shu L, Guo K, Lin ZH, Liu H. Long non-coding RNA HAGLROS promotes the development of diffuse large B-cell lymphoma via suppressing miR-100. J Clin Lab Anal 2021;:e24168. [PMID: 34888946 DOI: 10.1002/jcla.24168] [Reference Citation Analysis]
18 Al-Juhaishi T, Al-Kindi SG. Outcomes of cardiac diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Int J Cardiol 2021;339:146-9. [PMID: 34324949 DOI: 10.1016/j.ijcard.2021.07.043] [Reference Citation Analysis]
19 Han J, Tang Y, Zhong M, Wu W. Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line. Mol Med Rep 2019;20:5064-74. [PMID: 31638226 DOI: 10.3892/mmr.2019.10756] [Reference Citation Analysis]
20 Gorodetskiy V, Probatova N, Obukhova T, Vasilyev V. Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases. Lupus Sci Med 2021;8:e000561. [PMID: 34785569 DOI: 10.1136/lupus-2021-000561] [Reference Citation Analysis]
21 Ritter Z, Zámbó K, Balogh P, Szöllősi D, Jia X, Balázs Á, Taba G, Dezső D, Horváth I, Alizadeh H, Tuch D, Vyas K, Hegedűs N, Kovács T, Szigeti K, Máthé D, Schmidt E. In situ lymphoma imaging in a spontaneous mouse model using the Cerenkov Luminescence of F-18 and Ga-67 isotopes. Sci Rep 2021;11:24002. [PMID: 34907289 DOI: 10.1038/s41598-021-03505-3] [Reference Citation Analysis]
22 Savani M, Gencturk M, Shanley R, Cayci Z, Wilke C, Warlick ED, He F, Janakiram M, Weisdorf DJ, Brunstein CG, Bachanova V. Surveillance Imaging after Autologous Hematopoietic Cell Transplantation Predicts Survival in Patients with Diffuse Large B Cell Lymphoma. Biol Blood Marrow Transplant 2020;26:272-7. [PMID: 31669174 DOI: 10.1016/j.bbmt.2019.10.013] [Reference Citation Analysis]
23 Zorofchian S, El-Achi H, Yan Y, Esquenazi Y, Ballester LY. Characterization of genomic alterations in primary central nervous system lymphomas. J Neurooncol 2018;140:509-17. [PMID: 30171453 DOI: 10.1007/s11060-018-2990-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
24 Yu H, Peng S, Han S, Chen X, Lyu Q, Lei T. Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms. Biomed Res Int 2021;2021:5514726. [PMID: 34250086 DOI: 10.1155/2021/5514726] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Valcarcel B, Ampuero GS, de la Cruz-Ku G, Enriquez DJ, Malpica L. Outcomes of HTLV-1 Carriers with Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Matched Cohort Study. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)02069-3. [PMID: 34690089 DOI: 10.1016/j.clml.2021.09.017] [Reference Citation Analysis]
26 Zheng Y, Si J, Yuan T, Ding S, Tian C. Immune targeted therapy for diffuse large B cell lymphoma. Blood Science 2021;3:136-48. [DOI: 10.1097/bs9.0000000000000095] [Reference Citation Analysis]
27 Wang L, Dong P, Hu W, Tian B. 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the diagnosis and follow-up of primary hepatic diffuse large B-cell Lymphoma: A clinical case report. Medicine (Baltimore) 2020;99:e18980. [PMID: 32000430 DOI: 10.1097/MD.0000000000018980] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Han EJ, Kim J, Park SY, O JH. Spontaneous Remission and Concomitant Progression in a Patient with DLBCL. Diagnostics (Basel) 2020;10:E950. [PMID: 33202678 DOI: 10.3390/diagnostics10110950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Istiadi H, Sadhana U, Puspasari D, Miranti IP, Karlowee V, Listiana DE, Prasetyo A. Role of Cell-Origin Profiling Using Immunohistochemistry to Predict the Survival of Patients with Diffuse Large B-Cell Lymphoma in Indonesia. Yonago Acta Med 2021;64:200-6. [PMID: 34025195 DOI: 10.33160/yam.2021.05.014] [Reference Citation Analysis]
30 Luo Q, Pan W, Zhou S, Wang G, Yi H, Zhang L, Yan X, Yuan L, Liu Z, Wang J, Chen H, Qiu M, Yang D, Sun J. A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma. Oncol Res 2020;28:331-44. [PMID: 32093809 DOI: 10.3727/096504020X15825405463920] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Gomolka RS, Korzynska A, Siemion K, Gabor-siatkowska K, Klonowski W. Automatic method for assessment of proliferation index in digital images of DLBCL tissue section. Biocybernetics and Biomedical Engineering 2019;39:30-7. [DOI: 10.1016/j.bbe.2018.09.004] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
32 Wu XB, Hou SL, Liu H. Systemic immune inflammation index, ratio of lymphocytes to monocytes, lactate dehydrogenase and prognosis of diffuse large B-cell lymphoma patients. World J Clin Cases 2021; 9(32): 9825-9834 [PMID: 34877321 DOI: 10.12998/wjcc.v9.i32.9825] [Reference Citation Analysis]
33 Hashmi AA, Iftikhar SN, Nargus G, Ahmed O, Asghar IA, Shirazi UA, Afzal A, Irfan M, Ali J. Double-Expressor Phenotype (BCL-2/c-MYC Co-expression) of Diffuse Large B-Cell Lymphoma and Its Clinicopathological Correlation. Cureus 2021;13:e13155. [PMID: 33692924 DOI: 10.7759/cureus.13155] [Reference Citation Analysis]
34 Alsagaby SA. Transcriptomics-Based Investigation of Molecular Mechanisms Underlying Apoptosis Induced by ZnO Nanoparticles in Human Diffuse Large B-Cell Lymphoma. IJN 2022;Volume 17:2261-81. [DOI: 10.2147/ijn.s355408] [Reference Citation Analysis]
35 Ollikainen RK, Kotkaranta PH, Kemppainen J, Teppo HR, Kuitunen H, Pirinen R, Turpeenniemi-Hujanen T, Kuittinen O, Kuusisto MEL. Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma. Leuk Lymphoma 2021;:1-10. [PMID: 33856274 DOI: 10.1080/10428194.2021.1913150] [Reference Citation Analysis]
36 Vila-Payeras A, Terrasa-Sagristá F, Nadal-Lladó C, Parera-Amer E. Systemic B-cell lymphoma with skin manifestation clinically resembling granuloma annulare. J Cutan Pathol 2021;48:607-10. [PMID: 33245143 DOI: 10.1111/cup.13779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wang Y, Tan J, Wu H, Yi C. High Glucose Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in A20 Murine Diffuse Large B-Cell Lymphoma Cells Through Increased Expression of High Mobility Group AT-Hook 2 (HMGA2). Med Sci Monit 2019;25:3860-8. [PMID: 31124542 DOI: 10.12659/MSM.916195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
38 Chen Y, Zhang Z, Fang Q, Jian H. Prognostic impact of platelet-to-lymphocyte ratio on diffuse large B-cell lymphoma: a meta-analysis. Cancer Cell Int 2019;19:245. [PMID: 31572062 DOI: 10.1186/s12935-019-0962-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Carreras J, Kikuti YY, Miyaoka M, Hiraiwa S, Tomita S, Ikoma H, Kondo Y, Ito A, Shiraiwa S, Hamoudi R, Ando K, Nakamura N. A Single Gene Expression Set Derived from Artificial Intelligence Predicted the Prognosis of Several Lymphoma Subtypes; and High Immunohistochemical Expression of TNFAIP8 Associated with Poor Prognosis in Diffuse Large B-Cell Lymphoma. AI 2020;1:342-60. [DOI: 10.3390/ai1030023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
40 Lee SY, Hue SS. Terminal deoxynucleotidyl transferase negative B-lymphoblastic leukaemia/lymphoma with CD138 expression. Pathology 2020;52:286-9. [PMID: 31883671 DOI: 10.1016/j.pathol.2019.09.020] [Reference Citation Analysis]
41 Lee CH, Jeon SY, Yhim HY, Kwak JY. Disseminated soft tissue diffuse large B-cell lymphoma involving multiple abdominal wall muscles: A case report. World J Clin Cases 2021; 9(28): 8557-8562 [PMID: 34754868 DOI: 10.12998/wjcc.v9.i28.8557] [Reference Citation Analysis]
42 Anastasiadou E, Seto AG, Beatty X, Hermreck M, Gilles ME, Stroopinsky D, Pinter-Brown LC, Pestano L, Marchese C, Avigan D, Trivedi P, Escolar DM, Jackson AL, Slack FJ. Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo. Clin Cancer Res 2021;27:1139-49. [PMID: 33208342 DOI: 10.1158/1078-0432.CCR-20-3139] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
43 Gajra A, Jeune-Smith Y, Kish J, Yeh TC, Hime S, Feinberg B. Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma. Immunotherapy 2020;12:725-32. [PMID: 32552151 DOI: 10.2217/imt-2020-0118] [Reference Citation Analysis]
44 Medeiros LJ, Spagnolo DV. Lymphoma 2020: an update on recent advances in pathobiology and application to clinical practice. Pathology 2020;52:1-5. [PMID: 31812272 DOI: 10.1016/j.pathol.2019.10.004] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
45 Sheng L, Fu D, Cao Y, Huo Y, Wang S, Shen R, Xu P, Cheng S, Wang L, Zhao W. Integrated Genomic and Transcriptomic Analyses of Diffuse Large B-Cell Lymphoma With Multiple Abnormal Immunologic Markers. Front Oncol 2022;12:790720. [DOI: 10.3389/fonc.2022.790720] [Reference Citation Analysis]
46 Xu H, Yu X, Yang Z, Song Q, Cheng S, He Z, Dai L. PAX5-activated lncRNA ARRDC1-AS1 accelerates the autophagy and progression of DLBCL through sponging miR-2355-5p to regulate ATG5. Life Sci 2021;286:119932. [PMID: 34499929 DOI: 10.1016/j.lfs.2021.119932] [Reference Citation Analysis]
47 Parente P, Zanelli M, Sanguedolce F, Mastracci L, Graziano P. Hodgkin Reed-Sternberg-Like Cells in Non-Hodgkin Lymphoma. Diagnostics (Basel) 2020;10:E1019. [PMID: 33261174 DOI: 10.3390/diagnostics10121019] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
48 El Hasbani G, Taher AT, Abi-Ghanem AS, Nassif S, Bizri AR, Uthman I. Polymyalgia rheumatica-like presentation in a case of diffuse large B-cell lymphoma: a diagnostic pitfall. J Int Med Res 2021;49:3000605211018595. [PMID: 34044637 DOI: 10.1177/03000605211018595] [Reference Citation Analysis]
49 Lee SF, Evens AM, Ng AK, Luque-Fernandez MA. Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: a Hong Kong population-based study. Sci Rep 2021;11:17950. [PMID: 34504223 DOI: 10.1038/s41598-021-97455-5] [Reference Citation Analysis]
50 Lopez-Santillan M, Lopez-Lopez E, Alvarez-Gonzalez P, Martinez G, Arzuaga-Mendez J, Ruiz-Diaz I, Guerra-Merino I, Gutierrez-Camino A, Martin-Guerrero I. Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review. Crit Rev Oncol Hematol 2021;165:103430. [PMID: 34339834 DOI: 10.1016/j.critrevonc.2021.103430] [Reference Citation Analysis]
51 Zhang T, Liu H, Jiao L, Zhang Z, He J, Li L, Qiu L, Qian Z, Zhou S, Gong W, Meng B, Ren X, Zhang H, Wang X. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL. J Immunother Cancer 2022;10:e004114. [PMID: 35365585 DOI: 10.1136/jitc-2021-004114] [Reference Citation Analysis]
52 Li X, He Z, Cheng B, Fang Q, Ma D, Lu T, Wei D, Kuang X, Tang S, Xiong J, Wang J. Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism. Cancer Biol Ther 2018;19:825-34. [PMID: 29969367 DOI: 10.1080/15384047.2018.1472188] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
53 Li P, Chai J, Chen Z, Liu Y, Wei J, Liu Y, Zhao D, Ma J, Wang K, Li X, Shao Y, Gong L, Zhang W, Guo S, Yan Q, Li M, Fan L, Wang Z. Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. Front Oncol 2021;11:622648. [PMID: 33747936 DOI: 10.3389/fonc.2021.622648] [Reference Citation Analysis]
54 Li X, Duan Y, Hao Y. Identification of super enhancer-associated key genes for prognosis of germinal center B-cell type diffuse large B-cell lymphoma by integrated analysis. BMC Med Genomics 2021;14:69. [PMID: 33663517 DOI: 10.1186/s12920-021-00916-z] [Reference Citation Analysis]
55 Chen X, Li X, Yang H, Xie J, Liu A. Diagnosis and staging of diffuse large B-cell lymphoma using label-free surface-enhanced Raman spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc 2022;267:120571. [PMID: 34752994 DOI: 10.1016/j.saa.2021.120571] [Reference Citation Analysis]
56 Zhao S, Zhang M, Zhang Y, Meng H, Wang Y, Liu Y, Jing J, Huang L, Sun M, Zhang Y, Zhang Q. The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis. Cancer Biol Med 2018;15:290-8. [PMID: 30197796 DOI: 10.20892/j.issn.2095-3941.2018.0047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
57 Holst JM, Enemark MB, Pedersen MB, Lauridsen KL, Hybel TE, Clausen MR, Frederiksen H, Møller MB, Nørgaard P, Plesner TL, Hamilton-Dutoit SJ, d'Amore F, Honoré B, Ludvigsen M. Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia. Cancers (Basel) 2021;13:5526. [PMID: 34771688 DOI: 10.3390/cancers13215526] [Reference Citation Analysis]
58 Tholen K, Kalmanson O, Francom CR, Prager JD. Tonsillectomy and hematologic malignancy: Should routine pediatric tonsillectomy specimens be sent to pathology? Int J Pediatr Otorhinolaryngol 2021;151:110924. [PMID: 34597876 DOI: 10.1016/j.ijporl.2021.110924] [Reference Citation Analysis]
59 Durani U, Ansell SM. CD5+ diffuse large B-cell lymphoma: a narrative review. Leuk Lymphoma 2021;:1-9. [PMID: 34284686 DOI: 10.1080/10428194.2021.1953010] [Reference Citation Analysis]
60 Kim E, Nam J, Chang W, Zulfugarov IS, Okhlopkova ZM, Olennikov D, Chirikova NK, Kim SW. Angelica gigas Nakai and Decursin Downregulate Myc Expression to Promote Cell Death in B-cell Lymphoma. Sci Rep 2018;8:10590. [PMID: 30002430 DOI: 10.1038/s41598-018-28619-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
61 Onaindia A, Santiago-Quispe N, Iglesias-Martinez E, Romero-Abrio C. Molecular Update and Evolving Classification of Large B-Cell Lymphoma. Cancers (Basel) 2021;13:3352. [PMID: 34283060 DOI: 10.3390/cancers13133352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Liu H, Liu S, Zhang Q, Hou S. Serum amyloid a and misfolded transthyretin protein may be two predictable biomarkers to relapsed/ refractory diffuse large B cell lymphoma. Asian Journal of Surgery 2022. [DOI: 10.1016/j.asjsur.2022.01.131] [Reference Citation Analysis]
63 Rodrigues‐fernandes CI, Souza LL, Santos‐costa SFD, Pontes HAR, Almeida OP, Vargas PA, Henao JR, Rahimi S, Brennan PA, Fonseca FP. Clinicopathological analysis of oral diffuse large B‐cell lymphoma, NOS: A systematic review. J Oral Pathol Med 2019;48:185-91. [DOI: 10.1111/jop.12802] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
64 Wu J, He Z, Zhu Y, Jiang C, Deng Y, Wei B. ASPM Predicts Poor Clinical Outcome and Promotes Tumorigenesis for Diffuse Large B-cell Lymphoma. Curr Cancer Drug Targets 2021;21:80-9. [PMID: 32933462 DOI: 10.2174/1568009620666200915090703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Kwon HJ, Yang JM, Lee JO, Lee JS, Paik JH. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma. J Transl Med 2018;16:320. [PMID: 30458835 DOI: 10.1186/s12967-018-1689-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
66 Mohammed AA, Rashed HE, Abdelrahman AE, Obaya AA, Toam M, Abdel Nour HM, Abdelhamid MI, Elsayed FM. C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma. Asian Pac J Cancer Prev 2019;20:1463-70. [PMID: 31127909 DOI: 10.31557/APJCP.2019.20.5.1463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
67 Sethi A, Tandon A, Mishra H, Singh I. Diffuse large B-cell lymphoma: An immunohistochemical approach to diagnosis. J Oral Maxillofac Pathol 2019;23:284-8. [PMID: 31516237 DOI: 10.4103/jomfp.JOMFP_294_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
68 Wu J, Miao Y, Qian C, Tao P, Wang X, Dong X, Li X, Lou J, Liang J, Xu W, Li J, Min H. Clinical characteristics and outcomes in HIV-associated diffuse large B-cell lymphoma in China: A retrospective single-center study. J Cancer 2021;12:2903-11. [PMID: 33854591 DOI: 10.7150/jca.51027] [Reference Citation Analysis]
69 Zhu Q, Li Y, Guo Y, Hu L, Xiao Z, Liu X, Wang J, Xu Q, Tong X. Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting miR-497-5p/PIM1 axis. J Cell Mol Med 2019;23:7395-405. [PMID: 31483572 DOI: 10.1111/jcmm.14601] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
70 Yassine F, Iqbal M, Murthy H, Kharfan-dabaja MA, Chavez JC. Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. Current Research in Translational Medicine 2020;68:159-70. [DOI: 10.1016/j.retram.2020.05.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
71 Balzarotti M, Magagnoli M, Canales MÁ, Corradini P, Grande C, Sancho JM, Zaja F, Quinson AM, Belsack V, Maier D, Carlo-Stella C. A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. Invest New Drugs 2021;39:1028-35. [PMID: 33523334 DOI: 10.1007/s10637-020-01054-6] [Reference Citation Analysis]
72 Cui J, Zhang S, He H, Mesquita RA. Primary Extra Nodal Diffuse Large B-Cell Lymphoma of the Maxillary Sinus with Symptoms of Acute Pulpitis. Case Reports in Dentistry 2022;2022:1-7. [DOI: 10.1155/2022/8875832] [Reference Citation Analysis]
73 Lu TX, Wu S, Zhou XY, Zhang Y, Hong TT, Cai DY, Hua HY, Qi XW, Wu XH. CD5+MYC+ predicts worse prognosis in diffuse large B-cell lymphoma. Exp Mol Pathol 2020;112:104326. [PMID: 31706988 DOI: 10.1016/j.yexmp.2019.104326] [Reference Citation Analysis]
74 Drillis G, Goulielmaki M, Spandidos DA, Aggelaki S, Zoumpourlis V. Non-coding RNAs (miRNAs and lncRNAs) and their roles in lymphogenesis in all types of lymphomas and lymphoid malignancies. Oncol Lett 2021;21:393. [PMID: 33777216 DOI: 10.3892/ol.2021.12654] [Reference Citation Analysis]
75 Xiong D, Li M, Zeng C. Construction and validation of a risk scoring model for diffuse large B-cell lymphoma based on ferroptosis-related genes and its association with immune infiltration. Transl Oncol 2021;16:101314. [PMID: 34920339 DOI: 10.1016/j.tranon.2021.101314] [Reference Citation Analysis]
76 Devin J, Kassambara A, Bruyer A, Moreaux J, Bret C. Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact. J Clin Med 2019;8:E1074. [PMID: 31336593 DOI: 10.3390/jcm8071074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
77 Xu H, Duan N, Wang Y, Sun N, Ge S, Li H, Jing X, Liang K, Zhang X, Liu L, Xue C, Zhang C. The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma. Pathology 2020;52:206-12. [PMID: 31883669 DOI: 10.1016/j.pathol.2019.09.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Wang S, Sun L. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway. Bioengineered 2021;12:8296-308. [PMID: 34565287 DOI: 10.1080/21655979.2021.1985346] [Reference Citation Analysis]
79 Zeng H, Wang J, Deng R, Chen Z. Primary Diffuse Large B-Cell Lymphoma of the Female Urethra: A Case Report and Review of the Literature. Onco Targets Ther 2020;13:13015-22. [PMID: 33376350 DOI: 10.2147/OTT.S283704] [Reference Citation Analysis]
80 Boudesco C, Verhoeyen E, Martin L, Chassagne-Clement C, Salmi L, Mhaidly R, Pangault C, Fest T, Ramla S, Jardin F, Wolz OO, Weber ANR, Garrido C, Jego G. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. Blood 2018;132:510-20. [PMID: 29871863 DOI: 10.1182/blood-2017-12-819706] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
81 Hashmi AA, Iftikhar SN, Nargus G, Ahmed O, Asghar IA, Shirazi UA, Afzal A, Irfan M, Ali J. Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma. Cureus 2021;13:e13120. [PMID: 33728138 DOI: 10.7759/cureus.13120] [Reference Citation Analysis]
82 Boonsakan P, Iamsumang W, Chantrathammachart P, Chayavichitsilp P, Suchonwanit P, Rutnin S. Prognostic Value of Concurrent Expression of C-MYC and BCL2 in Intravascular Large B-Cell Lymphoma: A 10-Year Retrospective Study. Biomed Res Int 2020;2020:1350820. [PMID: 32566654 DOI: 10.1155/2020/1350820] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Aitamer M, Akil H, Vignoles C, Branchaud M, Abraham J, Gachard N, Feuillard J, Jauberteau MO, Shirvani H, Troutaud D, Bentayeb H. CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles. Br J Cancer 2021;125:1687-98. [PMID: 34743199 DOI: 10.1038/s41416-021-01611-7] [Reference Citation Analysis]
84 Cummin TEC, Cox KL, Murray TD, Turaj AH, Dunning L, English VL, Fell R, Packham G, Ma Y, Powell B, Johnson PWM, Cragg MS, Carter MJ. BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression. Blood Adv 2020;4:3316-28. [PMID: 32717030 DOI: 10.1182/bloodadvances.2020002231] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
85 Jeon BE, Kwon CS, Lee JE, Moon K, Cha J, Park I, Koh S, Yoon M, Kim SW, Kim JN. Anticancer Activity of Continentalic Acid in B-Cell Lymphoma. Molecules 2021;26:6845. [PMID: 34833935 DOI: 10.3390/molecules26226845] [Reference Citation Analysis]
86 Yang X, Fang D, Li M, Chen J, Cheng Y, Luo J. Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells. Med Sci Monit 2021;27:e929431. [PMID: 33764958 DOI: 10.12659/MSM.929431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Pennisi MS, Stella S, Vitale SR, Puma A, Di Gregorio S, Romano C, Tirrò E, Massimino M, Antolino A, Siragusa S, Mannina D, Impera S, Musolino C, Mineo G, Martino B, Zammit V, Di Raimondo F, Manzella L, Stagno F, Vigneri P. BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors. Front Oncol 2019;9:764. [PMID: 31456947 DOI: 10.3389/fonc.2019.00764] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
88 Nordmo C, Glehr G, Altenbuchinger M, Spang R, Ziepert M, Horn H, Staiger AM, Ott G, Schmitz N, Held G, Einsele H, Topp M, Rosenwald A, Rauert-Wunderlich H. Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma. Leuk Lymphoma 2021;62:1107-15. [PMID: 33353431 DOI: 10.1080/10428194.2020.1861268] [Reference Citation Analysis]
89 Huang Y, Lin Y, Song X, Wu D. LINC00857 contributes to proliferation and lymphomagenesis by regulating miR-370-3p/CBX3 axis in diffuse large B-cell lymphoma. Carcinogenesis 2021;42:733-41. [PMID: 33657224 DOI: 10.1093/carcin/bgab013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Yu L, Yu TT, Young KH. Cross-talk between Myc and p53 in B-cell lymphomas. Chronic Dis Transl Med 2019;5:139-54. [PMID: 31891126 DOI: 10.1016/j.cdtm.2019.08.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
91 Zhao J, Su L, Zhong J. Risk Factors for Cancer-specific Mortality and Cardiovascular Mortality in Patients With Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk 2020;20:e858-63. [PMID: 32680777 DOI: 10.1016/j.clml.2020.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Rodrigues-Fernandes CI, Junior AG, Soares CD, Morais TML, do Amaral-Silva GK, de Carvalho MGF, de Souza LL, Pires FR, Dos Santos TCRB, Pereira DL, Rivero LF, Bezerra KT, de Andrade BAB, Romañach MJ, Agostini M, Henao JR, Gabriel AF, Dos Santos Pinto Júnior D, Martins MD, Pereira MJC, Mesquita RA, Gomez RS, Souto GR, Santos-Silva AR, Vargas PA, Lopes MA, de Almeida OP, Pontes FSC, Pontes HAR, Burbano RMR, Fonseca FP. Oral and oropharyngeal diffuse large B-cell lymphoma and high-grade B-cell lymphoma: A clinicopathologic and prognostic study of 69 cases. Oral Surg Oral Med Oral Pathol Oral Radiol 2021;131:452-462.e4. [PMID: 33610538 DOI: 10.1016/j.oooo.2020.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
93 Zhao F, Qin Y, Yang J, Liu P, He X, Zhou L, Zhou S, Gui L, Zhang H, Wang X, Jiang S, Zhong Q, Zhou Y, Shi Y. R-CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B-cell lymphoma. Asia Pac J Clin Oncol 2020;16:385-91. [PMID: 32779387 DOI: 10.1111/ajco.13396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Kaplan D. Anatomical site as a parameter in the predictive model of diffuse large B cell lymphoma. Leuk Res 2019;76:112-3. [PMID: 30473330 DOI: 10.1016/j.leukres.2018.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Lee SF, Luque-Fernandez MA, Chen YH, Catalano PJ, Chiang CL, Wan EY, Wong IC, Chen MH, Ng AK. Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong. Blood Adv 2020;4:5107-17. [PMID: 33085755 DOI: 10.1182/bloodadvances.2020002737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Chavez JC, Yassine F, Sandoval-Sus J, Kharfan-Dabaja MA. Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. Int J Hematol Oncol 2021;10:IJH33. [PMID: 34540198 DOI: 10.2217/ijh-2020-0021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Zhang W, Li Q, Yang C, Yang H, Rao J, Zhang X. Curcumin exerts anti-tumor effects on diffuse large B cell lymphoma via regulating PPARγ expression. Biochemical and Biophysical Research Communications 2020;524:70-6. [DOI: 10.1016/j.bbrc.2019.12.129] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Bumbea H, Popov VM, Tomuleasa C, Omer M, Dobrea C, Manea I, Zurac S, Popp C, Dumitru I, Simoiu M, Mastalier B. Coexistence of Trisomy 8 and 13 in a Newly Diagnosed Patient With Diffuse Large B Cell Non-Hodgkin Lymphoma and Acute Myeloid Leukemia Secondary to Primary Myelofibrosis. Cureus. [DOI: 10.7759/cureus.22217] [Reference Citation Analysis]
99 Gao HX, Li SJ, Niu J, Ma ZP, Nuerlan A, Xue J, Wang MB, Cui WL, Abulajiang G, Sang W, Zhang W, Li XX. TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods. Pathol Res Pract 2020;216:152799. [PMID: 31932115 DOI: 10.1016/j.prp.2019.152799] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
100 Li Y, Zhang PY, Yang ZW, Ma F, Li FX. TIMD4 exhibits regulatory capability on the proliferation and apoptosis of diffuse large B-cell lymphoma cells via the Wnt/β-catenin pathway. J Gene Med 2020;22:e3186. [PMID: 32187802 DOI: 10.1002/jgm.3186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
101 Wu Y, Gu H, Bao Y, Lin T, Wang Z, Gu D, Shen H, Xian H, Fan Y, Mao R. USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma. Cell Biochem Funct 2022. [PMID: 35411950 DOI: 10.1002/cbf.3702] [Reference Citation Analysis]
102 Ge J, Xia Y, Sun Z, Zhang L, Li X, Li L, Wang X, Zhang X, Li Z, Nan F, Wan W, Xu D, Ding J, Fu X, Zhang M. Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation. Leuk Lymphoma 2022;:1-6. [PMID: 34989286 DOI: 10.1080/10428194.2021.2023742] [Reference Citation Analysis]
103 Xu J, Liu JL, Medeiros LJ, Huang W, Khoury JD, McDonnell TJ, Tang G, Schlette E, Yin CC, Bueso-Ramos CE, Lin P, Li S. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma. Eur J Haematol 2020;104:336-43. [PMID: 31944390 DOI: 10.1111/ejh.13384] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
104 Li WX, Dai SX, An SQ, Sun T, Liu J, Wang J, Liu LG, Xun Y, Yang H, Fan LX, Zhang XL, Liao WQ, You H, Tamagnone L, Liu F, Huang JF, Liu D. Transcriptome integration analysis and specific diagnosis model construction for Hodgkin's lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. Aging (Albany NY) 2021;13:11833-59. [PMID: 33885377 DOI: 10.18632/aging.202882] [Reference Citation Analysis]
105 Yang H, Qiu B, Chen S, Xun Y, Pan Y, Chen M, Li WX, Liao W, El-Ashram S, Yang A, Liu F. Soluble CXCL16 promotes TNF-α-induced apoptosis in DLBCL via the AMAD10-NF-κB regulatory feedback loop. Cell Biol Int 2019;43:863-74. [PMID: 31033093 DOI: 10.1002/cbin.11154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
106 Derouane F, Brigitte H, Placide N. Epithelioid angiosarcoma arising after an endovascular aneurysm repair: case report and review of the literature. Acta Clin Belg 2021;76:397-401. [PMID: 32186994 DOI: 10.1080/17843286.2020.1742489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
107 Su W, Niu X, Ji H, Xu Y, Zhong L, Wang S, Tang D, Zhou X, Zhang Q, Zhou J. A novel classification based on B-cell receptor signal gene expression correlates with prognosis in primary breast diffuse large B-cell lymphoma. J Cancer 2020;11:2431-41. [PMID: 32201514 DOI: 10.7150/jca.39083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Lin Y, Wang J, Xu M, Qiu C, Xu P, Shang L, He B, Wang F, Yue Y, Guo Y, Li F, Dong W, Xie X, Wang Y, Gu W. Summed rest score in gated myocardial perfusion imaging is a good predicator for treatment-related cardiotoxicity after anthracycline chemotherapy in patients with diffuse large B-cell lymphoma. Oncol Lett 2020;20:330. [PMID: 33133255 DOI: 10.3892/ol.2020.12194] [Reference Citation Analysis]
109 Morland D, Zizi G, Godard F, Gauchy AC, Durot C, Hoeffel C, Delmer A, Papathanassiou D, Durot E. 18F-FDG cerebellum/liver index as a prognostic factor for progression-free survival in diffuse large B-cell lymphoma. Ann Nucl Med 2021;35:785-93. [PMID: 34031852 DOI: 10.1007/s12149-021-01609-4] [Reference Citation Analysis]
110 Mehta A, Verma A, Gupta G, Tripathi R, Sharma A. Double Hit and Double Expresser Diffuse Large B Cell Lymphoma Subtypes: Discrete Subtypes and Major Predictors of Overall Survival. Indian J Hematol Blood Transfus 2020;36:627-34. [PMID: 33100703 DOI: 10.1007/s12288-019-01248-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
111 Biagioni A, Tavakol S, Ahmadirad N, Zahmatkeshan M, Magnelli L, Mandegary A, Samareh Fekri H, Asadi MH, Mohammadinejad R, Ahn KS. Small nucleolar RNA host genes promoting epithelial-mesenchymal transition lead cancer progression and metastasis. IUBMB Life 2021;73:825-42. [PMID: 33938625 DOI: 10.1002/iub.2501] [Reference Citation Analysis]
112 Aljoundi AK, Agoni C, Olotu FA, Soliman ME. 'Piperazining' the catalytic gatekeepers: unraveling the pan-inhibition of SRC kinases; LYN, FYN and BLK by masitinib. Future Med Chem 2019;11:2365-80. [PMID: 31516031 DOI: 10.4155/fmc-2018-0354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
113 Zhou Z, Zhang L, Wang X, Li X, Li L, Fu X, Zhang X, Li Z, Sun Z, Zhang M. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma. Ann Hematol 2021;100:1509-16. [PMID: 33900450 DOI: 10.1007/s00277-021-04535-7] [Reference Citation Analysis]
114 Pi M, Kuang H, Yue C, Yang Q, Wu A, Li Y, Assaraf YG, Yang D, Wu S. Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma. Drug Resistance Updates 2022;61:100822. [DOI: 10.1016/j.drup.2022.100822] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Beutler BD, Krishan R, Parafianowicz P, Ulanja MB, Elliott C, France J, Islam R, Gullapalli N. ABC-type diffuse large B-cell lymphoma presenting as rotator cuff tendinopathy: A diagnostic dilemma and review of the literature. Clin Case Rep 2020;8:327-32. [PMID: 32128182 DOI: 10.1002/ccr3.2630] [Reference Citation Analysis]
116 Yang H, Zhang P, Li J, Gao Y, Zhao L, Li J, Guo M, Zhang J, Li H, Wang F, Yuan Y. Targeting PIN-1 Attenuates GCB DLBCL Cell Proliferation Through Inhibition of PI3K/AKT Signaling. Onco Targets Ther 2020;13:8593-600. [PMID: 32904547 DOI: 10.2147/OTT.S247429] [Reference Citation Analysis]
117 Sun JJ, Liu L, Wang JR, Shen YZ, Qi TK, Wang ZY, Tang Y, Song W, Chen J, Zhang RF. Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China. Chin Med J (Engl) 2020;133:2796-802. [PMID: 33273327 DOI: 10.1097/CM9.0000000000001180] [Reference Citation Analysis]
118 Haslauer T, Greil R, Zaborsky N, Geisberger R. CAR T-Cell Therapy in Hematological Malignancies. Int J Mol Sci 2021;22:8996. [PMID: 34445701 DOI: 10.3390/ijms22168996] [Reference Citation Analysis]
119 Basu S, Agarwal R, Srivastava V. Deep discriminative learning model with calibrated attention map for the automated diagnosis of diffuse large B-cell lymphoma. Biomedical Signal Processing and Control 2022;76:103728. [DOI: 10.1016/j.bspc.2022.103728] [Reference Citation Analysis]
120 Li Z, Gu X, Rao D, Lu M, Wen J, Chen X, Wang H, Cui X, Tang W, Xu S, Wang P, Yu L, Ge X. Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation. Transl Oncol 2021;14:101129. [PMID: 34051623 DOI: 10.1016/j.tranon.2021.101129] [Reference Citation Analysis]
121 Bouabdallah S, Mariko ML, Besson J, Dellis O. [Rituximab in the treatment of diffuse large B-cell lymphoma: The CACNA1C subunit of channel Cav1.2 expression linked to certain forms of resistance]. Med Sci (Paris) 2021;37:406-8. [PMID: 33908862 DOI: 10.1051/medsci/2021043] [Reference Citation Analysis]
122 Michi Y, Harada H, Oikawa Y, Okuyama K, Kugimoto T, Kuroshima T, Hirai H, Mochizuki Y, Shimamoto H, Tomioka H, Kachi H, Sakamoto JI, Kayamori K, Yoda T. Clinical manifestations of diffuse large B-cell lymphoma that exhibits initial symptoms in the maxilla and mandible: a single-center retrospective study. BMC Oral Health 2022;22:20. [PMID: 35081952 DOI: 10.1186/s12903-022-02056-x] [Reference Citation Analysis]
123 Knerr JM, Kledal TN, Rosenkilde MM. Molecular Properties and Therapeutic Targeting of the EBV-Encoded Receptor BILF1. Cancers (Basel) 2021;13:4079. [PMID: 34439235 DOI: 10.3390/cancers13164079] [Reference Citation Analysis]
124 Marchesi F, Regazzo G, Palombi F, Terrenato I, Sacconi A, Spagnuolo M, Donzelli S, Marino M, Ercolani C, Di Benedetto A, Blandino G, Ciliberto G, Mengarelli A, Rizzo MG. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. J Exp Clin Cancer Res 2018;37:95. [PMID: 29716630 DOI: 10.1186/s13046-018-0768-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
125 Statuto T, D'Auria F, Del Vecchio L, Mansueto GR, Villani O, Lalinga AV, Possidente L, Nozza F, Vona G, Rago L, Storto G, Gasparini VR, Zambello R, D'Arena G, Valvano L. Atypical Mature T-Cell Neoplasms: The Relevance of the Role of Flow Cytometry. Onco Targets Ther 2020;13:7605-14. [PMID: 32848413 DOI: 10.2147/OTT.S258512] [Reference Citation Analysis]
126 Shi Y, Ding D, Qu R, Tang Y, Hao S. Non-Coding RNAs in Diffuse Large B-Cell Lymphoma. Onco Targets Ther 2020;13:12097-112. [PMID: 33262609 DOI: 10.2147/OTT.S281810] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
127 Magnoli F, Bernasconi B, Vivian L, Proserpio I, Pinotti G, Campiotti L, Mazzucchelli L, Sessa F, Tibiletti MG, Uccella S. Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases. Cancer Genet 2018;228-229:28-40. [PMID: 30553470 DOI: 10.1016/j.cancergen.2018.08.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
128 Jiménez-Cortegana C, Palazón-Carrión N, Martin Garcia-Sancho A, Nogales-Fernandez E, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Rueda Dominguez A, Casanova-Espinosa M, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Labrador J, Salar-Silvestre A, Rodriguez-Abreu D, Galvez-Carvajal L, Provencio M, Sánchez-Beato M, Guirado-Risueño M, Espejo-García P, Lejeune M, Álvaro T, Sánchez-Margalet V, de la Cruz-Merino L; Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA)., Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA)., Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA). Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial. J Immunother Cancer 2021;9:e002323. [PMID: 34158317 DOI: 10.1136/jitc-2020-002323] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
129 Zhang T, Ren T, Song Z, Zhao J, Jiao L, Zhang Z, He J, Liu X, Qiu L, Li L, Zhou S, Meng B, Zhai Q, Ren X, Qian Z, Wang X, Zhang H. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma. J Immunol Res 2020;2020:6968595. [PMID: 33178839 DOI: 10.1155/2020/6968595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
130 Pinto S, Naia L, Ferreira G, Eulálio M. T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Challenging Diagnosis. Eur J Case Rep Intern Med 2019;6:001077. [PMID: 31508381 DOI: 10.12890/2019_001077] [Reference Citation Analysis]
131 Choueiry F, Singh S, Sircar A, Laliotis G, Sun X, Chavdoula E, Zhang S, Helmig-Mason J, Hart A, Epperla N, Tsichlis P, Baiocchi R, Alinari L, Zhu J, Sehgal L. Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma. Cancers (Basel) 2021;13:2146. [PMID: 33946867 DOI: 10.3390/cancers13092146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Siqueira JM, Fernandes PM, de Oliveira ACF, Vassallo J, Alves FA, Jaguar GC. Primary diffuse large B-cell lymphoma of the mandible. Autops Case Rep 2019;9:e2019109. [PMID: 31528626 DOI: 10.4322/acr.2019.109] [Reference Citation Analysis]
133 Chen Y, Lin C, Zhang B. Non-Hodgkin Lymphoma With Longitudinally Extensive Transverse Myelopathy as the Initial Symptom: A Case Report. Front Oncol 2019;9:266. [PMID: 31032227 DOI: 10.3389/fonc.2019.00266] [Reference Citation Analysis]
134 King ML, Vengaloor Thomas T, Albert AA, Joseph S, Ramachandran Nair L, Lam JT, Woods WC, Nittala M, Vijayakumar S. A Case of Transformation of Primary Cutaneous Follicle Center Lymphoma to Diffuse Large B-Cell Lymphoma Involving the Parotid Gland and Cervical Lymph Nodes. Am J Case Rep 2019;20:1273-8. [PMID: 31462626 DOI: 10.12659/AJCR.917389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Mupamombe CT, Noel J, Laskar DB, Valdivia L. Cardiac Involvement by HIV-Associated DLBCL. Case Rep Med 2018;2018:7531319. [PMID: 30154859 DOI: 10.1155/2018/7531319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
136 Ma J, Redmond D, Miyaguchi A, Nam AS, Nie K, Mathew S, Elemento O, Tam W. Exploring tumor clonal evolution in bone marrow of patients with diffuse large B-cell lymphoma by deep IGH sequencing and its potential relevance in relapse. Blood Cancer J 2019;9:69. [PMID: 31434873 DOI: 10.1038/s41408-019-0229-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
137 Barraclough A, Alzahrani M, Ettrup MS, Bishton M, van Vliet C, Farinha P, Gould C, Birch S, Sehn LH, Sovani V, Ward MS, Augustson B, Biccler J, Connors JM, Scott DW, Gandhi MK, Savage KJ, El-Galaly T, Villa D, Cheah CY. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Adv 2019;3:2013-21. [PMID: 31285189 DOI: 10.1182/bloodadvances.2019000251] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
138 Dholaria B, Vanegas YAM, Diehl N, Spaulding AC, Visscher S, Tun HW, Ailawadhi S, Vishnu P. Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features. Clin Hematol Int 2020;2:117-24. [PMID: 34595452 DOI: 10.2991/chi.d.200410.001] [Reference Citation Analysis]
139 Patriarca A, Gaidano G. Investigational drugs for the treatment of diffuse large B-cell lymphoma. Expert Opin Investig Drugs 2021;30:25-38. [PMID: 33295827 DOI: 10.1080/13543784.2021.1855140] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
140 Wu P, Ma T, Chen Y, Wang F, Chen Y, Gao J, Zhou Z, Jia Y. Treatment of refractory diffuse large B-cell lymphoma by chidamide combined with autologous stem cell transplantation: a case report. Anticancer Drugs 2021;32:886-9. [PMID: 34145178 DOI: 10.1097/CAD.0000000000001093] [Reference Citation Analysis]
141 Pei SN, Wang MC, Ma MC, Kuo CY, Liao CK, Qiu H, Rothwell LA, Liu Y. A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan. Sci Rep 2021;11:10069. [PMID: 33980914 DOI: 10.1038/s41598-021-89316-y] [Reference Citation Analysis]
142 Valenzuela J, Yeaney GA, Hsi ED, Azzato EM, Peereboom DM, Singh AD. Large B-cell lymphoma of the uvea: Histopathologic variants and clinicopathologic correlation. Survey of Ophthalmology 2020;65:361-70. [DOI: 10.1016/j.survophthal.2019.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
143 Tseng CH, Wang WC, Chen CY, Hsu HJ, Chen YK. Clinical manifestations of oral lymphomas - Retrospective study of 15 cases in a Taiwanese population and a review of 592 cases from the literature. J Formos Med Assoc 2021;120:361-70. [PMID: 32505589 DOI: 10.1016/j.jfma.2020.05.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
144 Candelaria M, González DE, Delamain MT, Bär DO, Beniwal SK, Dasappa L, Flores DH, Querol J, Guan TS, Lipatov ON, Volodicheva EM, Patel M, Safaee Nodehi SR, Fogliatto L, Paravisini A, Perez Diaz L; RTXM83 study. Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study. Leuk Lymphoma 2019;60:3375-85. [PMID: 31272251 DOI: 10.1080/10428194.2019.1633632] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
145 Perez de Acha O, Rossi M, Gorospe M. Circular RNAs in Blood Malignancies. Front Mol Biosci 2020;7:109. [PMID: 32676504 DOI: 10.3389/fmolb.2020.00109] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
146 Cascione L, Aresu L, Baudis M, Bertoni F. DNA Copy Number Changes in Diffuse Large B Cell Lymphomas. Front Oncol 2020;10:584095. [PMID: 33344238 DOI: 10.3389/fonc.2020.584095] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
147 Ma XB, Zhong YP, Zheng Y, Jiang J, Wang YP. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma. Cancer Med 2018;7:4284-95. [PMID: 30019388 DOI: 10.1002/cam4.1674] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
148 Martín-Moro F, Piris-Villaespesa M, Marquet-Palomanes J, García-Cosío M, Villarrubia J, Lario A, García I, Michael B, Roldán E, García-Vela JA, Lopez-Jiménez J. Bone marrow infiltration by flow cytometry at diffuse large B-cell lymphoma NOS diagnosis implies worse prognosis without considering bone marrow histology. Cytometry B Clin Cytom 2020;98:525-8. [PMID: 31873987 DOI: 10.1002/cyto.b.21863] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
149 Singh B, Gogia P, Kaur P, Guragai N, Maroules M. Hypercalcaemia, Renal Dysfunction, Anaemia, Bone Disease (CRAB Criteria): A Case of Lymphoma. Eur J Case Rep Intern Med 2020;7:002140. [PMID: 33585332 DOI: 10.12890/2020_002140] [Reference Citation Analysis]
150 Shao C, Guo Y, Xu X, Pan D, Wang B, Tang Y, Xu S. Non-pyothorax-associated primary pleural lymphoma without pleural effusion in an immunocompetent patient: a case report and literature review. J Thorac Dis 2018;10:E368-71. [PMID: 29997996 DOI: 10.21037/jtd.2018.04.163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
151 Qiao LY, Li HB, Zhang Y, Shen D, Liu P, Che YQ. CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance. Pharmgenomics Pers Med 2021;14:591-9. [PMID: 34079334 DOI: 10.2147/PGPM.S310816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
152 Pan BH, Kong YL, Wang L, Zhu HY, Li XT, Liang JH, Xia Y, Wu JZ, Fan L, Li JY, Xu W. The prognostic roles of hypogammaglobulinemia and hypocomplementemia in newly diagnosed diffuse large B-cell lymphoma. Leuk Lymphoma 2021;62:291-9. [PMID: 33063579 DOI: 10.1080/10428194.2020.1832673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
153 Aide N, Fruchart C, Nganoa C, Gac AC, Lasnon C. Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy. Eur Radiol 2020;30:4623-32. [PMID: 32248365 DOI: 10.1007/s00330-020-06815-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
154 Hatzl S, Posch F, Rezai A, Gornicec M, Beham-Schmid C, Magnes T, Wangner S, Deutsch A, Greinix H, Uhl B, Prochazka KT, Egle A, Greil R, Melchardt T, Linkesch W, Schulz E, Neumeister P. Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. Support Care Cancer 2021;29:5197-207. [PMID: 33625586 DOI: 10.1007/s00520-021-06059-2] [Reference Citation Analysis]
155 Abdulla M, Hollander P, Pandzic T, Mansouri L, Ednersson SB, Andersson PO, Hultdin M, Fors M, Erlanson M, Degerman S, Petersen HM, Asmar F, Grønbaek K, Enblad G, Cavelier L, Rosenquist R, Amini RM. Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma. Am J Hematol 2020;95:57-67. [PMID: 31659781 DOI: 10.1002/ajh.25666] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
156 Shah J, Shacham S, Kauffman M, Daniele P, Tomaras D, Tremblay G, Casasnovas RO, Maerevoet M, Zijlstra J, Follows G, P Vermaat JS, Kalakonda N, Goy AH, Choquet S, Den Neste EV, Hill BT, Thieblemont C, Cavallo F, la Cruz F, Kuruvilla J, Hamad N, Bouabdallah R, Jäger U, Caimi P, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vasilakopoulos TP, Samal P, Nagy A, Ku M, Canales Albendea MÁ. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. Future Oncol 2021;17:1295-310. [PMID: 33528286 DOI: 10.2217/fon-2020-0946] [Reference Citation Analysis]
157 Xia Y, Huang S, Wang Y, Lei D, Wang Y, Yang H, Gao Y, Liu P. Prognostication of Primary Tumor Location in Early-Stage Nodal Diffuse Large B-Cell Lymphoma: An Analysis of the SEER Database. Cancers (Basel) 2021;13:3954. [PMID: 34439110 DOI: 10.3390/cancers13163954] [Reference Citation Analysis]
158 Hashmi AA, Haider R, Nargus G, Ahmed O, Yaqeen SR, Asghar IA, Afzal A, Irfan M, Edhi MM, Ali J. CD30-Positive Anaplastic Variant of Diffuse Large B-cell Lymphoma: Frequency and Association With Clinicopathological Parameters. Cureus 2021;13:e13209. [PMID: 33717748 DOI: 10.7759/cureus.13209] [Reference Citation Analysis]
159 Erginoz E, Askar A, Cavus GH, Velidedeoglu M. Primary diffuse large B-cell lymphoma of the sigmoid colon. Int J Surg Case Rep 2021;87:106454. [PMID: 34600235 DOI: 10.1016/j.ijscr.2021.106454] [Reference Citation Analysis]
160 Nesic M, El-Galaly TC, Bøgsted M, Pedersen IS, Dybkær K. Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma. Expert Rev Hematol 2020;13:655-68. [PMID: 32293210 DOI: 10.1080/17474086.2020.1755958] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
161 Candelaria M, Dueñas-Gonzalez A. Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. Ther Adv Hematol 2021;12:2040620721989579. [PMID: 33796235 DOI: 10.1177/2040620721989579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Uluköylü Mengüç M, Mehtap Ö, Dağlıöz Görür G, Birtaş Ateşoğlu E, Gedük A, Ünal S, Tarkun P, Hacıhanefioğlu A. The Role of Interim PET/CT on Survival in Diffuse Large B Cell Lymphoma. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)00241-X. [PMID: 34353778 DOI: 10.1016/j.clml.2021.06.016] [Reference Citation Analysis]
163 Coleman M, Belada D, Casasnovas RO, Gressin R, Lee HP, Mehta A, Munoz J, Verhoef G, Corrado C, DeMarini DJ, Zhao W, Li J, Fay K. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). Leuk Lymphoma 2021;62:368-76. [PMID: 33140664 DOI: 10.1080/10428194.2020.1832660] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
164 Zhang L, Zhou S, Zhou T, Li X, Tang J. Potential of the tumor‑derived extracellular vesicles carrying the miR‑125b‑5p target TNFAIP3 in reducing the sensitivity of diffuse large B cell lymphoma to rituximab. Int J Oncol 2021;58:31. [PMID: 33887878 DOI: 10.3892/ijo.2021.5211] [Reference Citation Analysis]
165 Lin D, Wang Y, Lei L, Lin C. Circ_0003645 serves as miR-335-5p sponge to promote the biological process of diffuse large B-cell lymphoma by upregulating NFIB. Autoimmunity 2022;:1-9. [PMID: 35001739 DOI: 10.1080/08916934.2021.2023863] [Reference Citation Analysis]
166 Daliparty VM, Amoozgar B, Mamidanna S, Kaushal V, Baloch ZA, Rehman F. Presentation of Diffuse Large B-Cell Lymphoma with Shoulder Pain: A Case Report. Am J Case Rep 2021;22:e927828. [PMID: 33434189 DOI: 10.12659/AJCR.927828] [Reference Citation Analysis]
167 Shi XX, Miao WM, Pang DW, Wu JS, Tong QS, Li JX, Luo JQ, Li WY, Du JZ, Wang J. Angiopep-2 conjugated nanoparticles loaded with doxorubicin for the treatment of primary central nervous system lymphoma. Biomater Sci 2020;8:1290-7. [PMID: 31899467 DOI: 10.1039/c9bm01750j] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
168 Ensor AM, Sanchez CG, Ensor JE, Anand K. Primary diffuse large B-cell lymphoma of the uterus: A SEER database analysis. Medicine (Baltimore) 2021;100:e27359. [PMID: 34622835 DOI: 10.1097/MD.0000000000027359] [Reference Citation Analysis]
169 Zhang H, Chi F, Qin K, Mu X, Wang L, Yang B, Wang Y, Bai M, Li Z, Su L, Yu B. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway. Mol Med Rep 2021;23:308. [PMID: 33649847 DOI: 10.3892/mmr.2021.11947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Gao HX, Li SJ, Wang MB, Yan SF, Cui WL, Ma ZP, Xue J, Sang W, Zhang W, Li XX. Screening and identification of differentially expressed microRNAs in diffuse large B-cell lymphoma based on microRNA microarray. Oncol Lett 2021;22:753. [PMID: 34539857 DOI: 10.3892/ol.2021.13014] [Reference Citation Analysis]
171 Heine R, Thielen FW, Koopmanschap M, Kersten MJ, Einsele H, Jaeger U, Sonneveld P, Sierra J, Smand C, Uyl-de Groot CA. Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future. Hemasphere 2021;5:e524. [PMID: 33880433 DOI: 10.1097/HS9.0000000000000524] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Betts EV, Rashidi HH, Olson KA. Educational Case: Gastric High-Grade B-Cell Lymphoma With MYC and BCL2 Gene Rearrangement (Double-Hit Lymphoma). Acad Pathol 2020;7:2374289520903415. [PMID: 32083169 DOI: 10.1177/2374289520903415] [Reference Citation Analysis]
173 Xiao Z, Tang Z, Zheng C, Luo J, Zhao K, Zhang Z. Diffusion Kurtosis Imaging and Intravoxel Incoherent Motion in Differentiating Nasal Malignancies. Laryngoscope 2020;130:E727-35. [PMID: 31747056 DOI: 10.1002/lary.28424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
174 Li X, Wei Y, Wei X. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma. Cancer Lett 2020;491:146-61. [PMID: 32798587 DOI: 10.1016/j.canlet.2020.07.032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
175 Skorka K, Ostapinska K, Malesa A, Giannopoulos K. The Application of CAR-T Cells in Haematological Malignancies. Arch Immunol Ther Exp (Warsz) 2020;68:34. [PMID: 33156409 DOI: 10.1007/s00005-020-00599-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
176 Mo Z, Wood S, Namiranian S, Mizukoshi R, Weng S, Jang IS, Fontanillo C, Baughman JM, Silva-Torres A, Slade M, Khater M, Wang K, Rolfe M, Lu G. Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen. Blood Adv 2021;5:2027-39. [PMID: 33847741 DOI: 10.1182/bloodadvances.2020003431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
177 Ermann DA, Vardell VA, Kallam A, Silberstein PT, Armitage JO. Academic Centers Compared With Nonacademic Centers for Patients With International Prognostic Index Risk-stratified Diffuse Large B-cell Lymphoma: A Survival Outcomes Analysis. Clinical Lymphoma Myeloma and Leukemia 2020;20:e174-83. [DOI: 10.1016/j.clml.2019.11.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
178 Sun M, Chen Z, Wu X, Yu Y, Wang L, Lu A, Zhang G, Li F. The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research. Front Immunol 2021;12:602330. [PMID: 33717084 DOI: 10.3389/fimmu.2021.602330] [Reference Citation Analysis]
179 Mohammed TJ, Gosain R, Sharma R, Torka P. Lactic acidosis: a unique presentation of diffuse large B-cell lymphoma. BMJ Case Rep 2019;12:e230277. [PMID: 31653622 DOI: 10.1136/bcr-2019-230277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
180 Garcia-Recio M, Wudhikarn K, Pennisi M, Alonso-Trillo R, Flynn J, Shouval R, Afuye AO, Silverberg ML, Batlevi CW, Dahi P, Devlin S, Giralt SA, Halton E, Ruiz J, Maloy M, Mead E, Palomba ML, Santomasso B, Sauter CS, Scordo M, Shah GL, Perales MA. The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther 2021;27:233-40. [PMID: 33781518 DOI: 10.1016/j.jtct.2020.10.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
181 Yoon S, Ryu KH, Baek HJ, An HJ, Joo YH. Epstein-Barr virus-positive diffuse large B-cell lymphoma with human immunodeficiency virus mimicking complicated frontal sinusitis: A case report. World J Clin Cases 2021; 9(7): 1654-1660 [PMID: 33728309 DOI: 10.12998/wjcc.v9.i7.1654] [Reference Citation Analysis]
182 Zhao P, Li L, Zhou S, Qiu L, Qian Z, Liu X, Meng B, Zhang H. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma. Hematol Oncol 2019;37:360-7. [PMID: 31359442 DOI: 10.1002/hon.2657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
183 Chen Y, Wang F, Wu P, Gong S, Gao J, Tao H, Shen Q, Wang S, Zhou Z, Jia Y. Artesunate induces apoptosis, autophagy and ferroptosis in diffuse large B cell lymphoma cells by impairing STAT3 signaling. Cell Signal 2021;88:110167. [PMID: 34628002 DOI: 10.1016/j.cellsig.2021.110167] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Tian C, Chen Z, Li Y. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma. J Int Med Res 2020;48:300060520936053. [PMID: 32643971 DOI: 10.1177/0300060520936053] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Li J, Huang Y, Zhang Y, Wen J, Chen Y, Wang L, Jiang P, Hu J. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma. Med Oncol 2021;38:33. [PMID: 33629212 DOI: 10.1007/s12032-021-01470-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
186 Miao Y, Chen X, Qin M, Zhou W, Wang Y, Ji Y. lncRNA GAS5, as a ceRNA, inhibits the proliferation of diffuse large B‑cell lymphoma cells by regulating the miR‑18a‑5p/RUNX1 axis. Int J Oncol 2021;59:94. [PMID: 34698360 DOI: 10.3892/ijo.2021.5274] [Reference Citation Analysis]
187 Aljoundi AK, Agoni C, Olotu FA, Soliman MES. Turning to Computer-aided Drug Design in the Treatment of Diffuse Large B-cell Lymphoma: Has it been Helpful? Anticancer Agents Med Chem 2019;19:1325-39. [PMID: 30950356 DOI: 10.2174/1871520619666190405111526] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
188 Prusila REI, Peroja P, Jantunen E, Turpeenniemi-Hujanen T, Kuittinen O. Treatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP-16). Hematol Oncol 2019;37:136-42. [PMID: 30589950 DOI: 10.1002/hon.2572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
189 Putri S, Setiawan E, Saldi SRF, Khoe LC, Sari ER, Megraini A, Nadjib M, Sastroasmoro S, Armansyah A. Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis. BMC Health Serv Res 2022;22:553. [PMID: 35468783 DOI: 10.1186/s12913-022-07956-w] [Reference Citation Analysis]
190 Wang Y, Guo D, Li B, Wang Y, Wang B, Wang Z, Wang M, Teng Q. MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1). Leuk Res 2021;112:106769. [PMID: 34875555 DOI: 10.1016/j.leukres.2021.106769] [Reference Citation Analysis]
191 Gupta A, Lee JA, Nguyen SA, Lentsch EJ. Primary diffuse large B-cell lymphoma of the major salivary glands: Increasing incidence and survival. Am J Otolaryngol 2021;42:102938. [PMID: 33524741 DOI: 10.1016/j.amjoto.2021.102938] [Reference Citation Analysis]
192 Zuo S, Yu J, Pan H, Lu L. Novel insights on targeting ferroptosis in cancer therapy. Biomark Res 2020;8:50. [PMID: 33024562 DOI: 10.1186/s40364-020-00229-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
193 Sukswai N, Lyapichev K, Khoury JD, Medeiros LJ. Diffuse large B-cell lymphoma variants: an update. Pathology 2020;52:53-67. [PMID: 31735345 DOI: 10.1016/j.pathol.2019.08.013] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
194 Kato S, Kubota Y, Sekiguchi M, Watanabe K, Shinozaki-Ushiku A, Takita J, Hiwatari M. KMT2A-rearranged diffuse large B-cell lymphoma in a child: a case report and molecular characterization. Pediatr Hematol Oncol 2021;38:281-9. [PMID: 33150819 DOI: 10.1080/08880018.2020.1838013] [Reference Citation Analysis]
195 Hu K, Li B, Ma R, Yi H, Xu Z, Peng Y, Yu D, Wu H, Cheng T, Lu Y, Zhang Y, Wei R, Yang G, Wu X, Zhu W, Shi J. Anti-DLBCL efficacy of DCZ0825 in vitro and in vivo: involvement of the PI3K‒AKT‒mTOR/JNK pathway. Acta Biochim Biophys Sin (Shanghai) 2021;53:575-83. [PMID: 33821934 DOI: 10.1093/abbs/gmab031] [Reference Citation Analysis]
196 de Andrade BAB, Silva Cunha JL, Abrahão AC, Agostini M, Corrêa Roza ALO, de Almeida OP, de Castro LA, Romañach MJ. A dome-shaped nodule on unattached alveolar mucosa. Oral Surg Oral Med Oral Pathol Oral Radiol 2021:S2212-4403(21)00561-7. [PMID: 34753691 DOI: 10.1016/j.oooo.2021.08.006] [Reference Citation Analysis]
197 Li Z, Yu F, Ye W, Mao L, Huang J, Shao Y, Yan J, Yu W, Jin J, Wang J. Clinical Features and Prognostic Significance of NOTCH1 Mutations in Diffuse Large B-Cell Lymphoma. Front Oncol 2021;11:746577. [DOI: 10.3389/fonc.2021.746577] [Reference Citation Analysis]
198 Sharma R, Heidari A, Cobos E, Petersen G, Ramzan AA, Polineni RD. Two Cases of Pelvic Diffuse Large B-Cell Lymphoma. J Investig Med High Impact Case Rep 2022;10:23247096221089505. [PMID: 35470733 DOI: 10.1177/23247096221089505] [Reference Citation Analysis]
199 Zhao C, Huang R, Zeng Z, Yang S, Lu W, Liu J, Wei Y, Guo H, Zhang Y, Yan P, Huang Z, Shi J. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients. Aging (Albany NY) 2021;13:14131-58. [PMID: 34001679 DOI: 10.18632/aging.203030] [Reference Citation Analysis]
200 Spira A, Zhou X, Chen L, Gnanasakthy A, Wang L, Ungar D, Curiel R, Liao L, Radford J, Kahl B. Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk 2021:S2152-2650(21)02031-0. [PMID: 34690090 DOI: 10.1016/j.clml.2021.09.001] [Reference Citation Analysis]
201 Ponzo G, Umana GE, Valastro M, Giuffrida M, Tranchina MG, Nicoletti GF, Scalia G. Cervical radiculopathy as first presentation of CD3-positive diffuse large B-cell lymphoma of the cervico-thoracic junction. Br J Neurosurg 2020;:1-4. [PMID: 33012208 DOI: 10.1080/02688697.2020.1828278] [Reference Citation Analysis]
202 Ohmoto A, Fuji S. Infection profiles of different chemotherapy regimens and the clinical feasibility of antimicrobial prophylaxis in patients with DLBCL. Blood Rev 2021;46:100738. [PMID: 32747325 DOI: 10.1016/j.blre.2020.100738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
203 Popp J, Viestenz A, Kisser U, Busse C, Wickenhauser C, Bethmann D, Struck HG, Heichel J. [Prophylactic intubation of the lacrimal duct in chemoradiotherapy of the lacrimal sac]. Ophthalmologe 2021. [PMID: 34043083 DOI: 10.1007/s00347-021-01402-8] [Reference Citation Analysis]
204 Jiménez-Cortegana C, Sánchez-Martínez PM, Palazón-Carrión N, Nogales-Fernández E, Henao-Carrasco F, Martín García-Sancho A, Rueda A, Provencio M, de la Cruz-Merino L, Sánchez-Margalet V. Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial. Cancers (Basel) 2021;13:4622. [PMID: 34572849 DOI: 10.3390/cancers13184622] [Reference Citation Analysis]
205 Pan M, Yang P, Wang F, Luo X, Li B, Ding Y, Lu H, Dong Y, Zhang W, Xiu B, Liang A. Whole Transcriptome Data Analysis Reveals Prognostic Signature Genes for Overall Survival Prediction in Diffuse Large B Cell Lymphoma. Front Genet 2021;12:648800. [PMID: 34178023 DOI: 10.3389/fgene.2021.648800] [Reference Citation Analysis]